Objective The data related to adverse drug reaction of trastuzumab deruxtecan(T-DXd)were mined to provide references for its clinical management and adverse event handling.Methods Based on the Food and Drug Administration Adverse Event Reporting System(FAERS)database,the data reported from the post-marketing period of T-DXd until the fourth quarter of 2024 were extracted.The proportion imbalance method,specifically the reporting odds ratio(ROR)method,was used to mine and analyze the data related to adverse events of T-DXd.Results A total of 13 134 cases of adverse events related to T-DXd were obtained from the FAERS database.Gastrointestinal disorders were the most common,with 2348 adverse reaction signals,accounting for 17.88％.The most frequent adverse reactions were nausea(n=809),interstitial lung disease(n=732),and fatigue(n=579).The one with the highest ROR value was Listeriosis gastroenteritis(ROR=1228.74).The highest number of deaths were from interstitial lung disease(226),pneumonitis(90),and nausea(67).Conclusion By mining data on real-world adverse drug reaction related to T-DXd,suggests that pulmonary function,cardiac function,complete blood count and other parameters should be closely monitored during treatment for early diagnosis and treatment of corresponding complications.

Objective To systematically analyze novel antibody-drug conjugates(ADCs)associated with breast cancer that cause interstitial lung disease(ILD),providing a reference for the safe clinical use of ADCs.Methods A total of 909 ILD adverse event reports Adverse event reports were collected,extracted from the US Food and Drug Administration Adverse Event Reporting System database.The correlation between trastuzumab deruxtecan(T-DXd),trastuzumab emtansine(T-DM1),and sacituzumab govitecan(SG)with ILD were evaluated using the reporting odds ratio(ROR)and proportional reporting ratio(PRR)methods from the disproportionality analysis.Descriptive analysis was performed on the main characteristics of ILD patients(gender,age,time of onset,and outcomes).Results Including 812 for T-DXd,84 for T-DM1,and 13 for SG.The ROR values were 15.97,2.21,and 0.41,respectively,and the PRR values were 15.33,2.19,and 0.41.T-DXd and T-DM1 showed significant correlations with ILD,with the risk signal strength of T-DXd being significantly higher than that of T-DM1.The median time to ILD onset for T-DXd,T-DM1,and SG was 76.0 days,66.0 days,and 53.5 days,respectively.The number of deaths caused by ILD was 265 cases,13 cases,and 1 case,respectively,with the first 180 days after initial administration being a critical monitoring period.Conclusion The risk of ILD induced by different ADC drugs exhibits significant heterogeneity.Clinicians must remain highly vigilant for ILD caused by these agents,emphasizing early diagnosis and treatment to reduce mortality.

Objective To systematically analyze novel antibody-drug conjugates(ADCs)associated with breast cancer that cause interstitial lung disease(ILD),providing a reference for the safe clinical use of ADCs.Methods A total of 909 ILD adverse event reports Adverse event reports were collected,extracted from the US Food and Drug Administration Adverse Event Reporting System database.The correlation between trastuzumab deruxtecan(T-DXd),trastuzumab emtansine(T-DM1),and sacituzumab govitecan(SG)with ILD were evaluated using the reporting odds ratio(ROR)and proportional reporting ratio(PRR)methods from the disproportionality analysis.Descriptive analysis was performed on the main characteristics of ILD patients(gender,age,time of onset,and outcomes).Results Including 812 for T-DXd,84 for T-DM1,and 13 for SG.The ROR values were 15.97,2.21,and 0.41,respectively,and the PRR values were 15.33,2.19,and 0.41.T-DXd and T-DM1 showed significant correlations with ILD,with the risk signal strength of T-DXd being significantly higher than that of T-DM1.The median time to ILD onset for T-DXd,T-DM1,and SG was 76.0 days,66.0 days,and 53.5 days,respectively.The number of deaths caused by ILD was 265 cases,13 cases,and 1 case,respectively,with the first 180 days after initial administration being a critical monitoring period.Conclusion The risk of ILD induced by different ADC drugs exhibits significant heterogeneity.Clinicians must remain highly vigilant for ILD caused by these agents,emphasizing early diagnosis and treatment to reduce mortality.

Objective The data related to adverse drug reaction of trastuzumab deruxtecan(T-DXd)were mined to provide references for its clinical management and adverse event handling.Methods Based on the Food and Drug Administration Adverse Event Reporting System(FAERS)database,the data reported from the post-marketing period of T-DXd until the fourth quarter of 2024 were extracted.The proportion imbalance method,specifically the reporting odds ratio(ROR)method,was used to mine and analyze the data related to adverse events of T-DXd.Results A total of 13 134 cases of adverse events related to T-DXd were obtained from the FAERS database.Gastrointestinal disorders were the most common,with 2348 adverse reaction signals,accounting for 17.88％.The most frequent adverse reactions were nausea(n=809),interstitial lung disease(n=732),and fatigue(n=579).The one with the highest ROR value was Listeriosis gastroenteritis(ROR=1228.74).The highest number of deaths were from interstitial lung disease(226),pneumonitis(90),and nausea(67).Conclusion By mining data on real-world adverse drug reaction related to T-DXd,suggests that pulmonary function,cardiac function,complete blood count and other parameters should be closely monitored during treatment for early diagnosis and treatment of corresponding complications.

Background: Galangin, commonly employed in traditional Chinese medicine for its diverse medicinal properties, exhibits potential in treating inflammatory pain. Nevertheless, its mechanism of action remains unclear. Methods: Mice were randomly divided into 4 groups for 7 days: a normal control group, a galangin-treated (25 and 50 mg/kg), and a positive control celecoxib (20 mg/kg). Analgesic and anti-inflammatory effects were evaluated using a hot plate test, acetic acid-induced writhing test, acetic acid-induced vascular permeability test, formalininduced paw licking test, and carrageenan-induced paw swelling test. The interplay between galangin, transient receptor potential vanilloid 1 (TRPV1), NF-κB, COX-2, and TNF-α proteins was evaluated via molecular docking. COX- 2, PGE2, IL-1β, IL-6, and TNF-α levels in serum were measured using ELISA after capsaicin administration (200 nmol/L). TRPV1 expression in the dorsal root ganglion was analyzed by Western blot. The quantities of substance P (SP) and calcitonin gene-related peptide (CGRP) were assessed using qPCR. Results: Galangin reduced hot plate-induced licking latency, acetic acid-induced contortions, carrageenantriggered foot inflammation, and capillary permeability in mice. It exhibited favorable affinity towards TRPV1, NF- κB, COX-2, and TNF-α, resulting in decreased levels of COX-2, PGE2, IL-1β, IL-6, and TNF-α in serum following capsaicin stimulation. Galangin effectively suppressed the upregulation of TRPV1 protein and associated receptor neuropeptides CGRP and SP mRNA, while concurrently inhibiting the expression of NF-κB, TNF-α, COX-2, and PGE2 mRNA. Conclusions Galangin exerts its anti-inflammatory pain effects by inhibiting TRPV1 activation and regulating COX-2, NF-κB/TNF-α expression, providing evidence for the use of galangin in the management of inflammatory pain.